HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kolár, Z Articles by Dusek, J Search for Related Content PubMed PubMed Citation Articles by Kolár, Z Articles by Dusek, J

Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer

Z Kolá¹, P G Murray³, K Scott⁴, A Harrison⁴, B Vojtek⁵ and J Duek²

¹ Centre of Molecular Biology and Medicine, Palack University, CZ-77515 Olomouc, Czech
² Institute of Pathology, Palack University
³ School of Health Sciences, University of Wolverhampton WV1 1DJ, UK
⁴ Department of Histopathology, New Cross Hospital, Wolverhampton WV10 0QP, UK
⁵ Masaryk Memorial Cancer Institute, Brno, Czech Republic

Correspondence: Professor Kolá email: kolarz{at}risc.upol.cz

Background—There is currently no effective treatment for recurrent hormone refractory carcinomas of the prostate gland. An understanding of the underlying mechanisms responsible for the progression of these lesions is likely to be important for the development of new therapeutic approaches. Recently, it has been suggested that the transition to a hormone independent state is accompanied by increased proliferation and bcl-2 gene expression, as well as by a decreased apoptotic state.

Aim—To investigate the possible role of Bcl-2 and other cell cycle regulating proteins in the development of prostatic tumours.

Methods—Immunohistochemistry was used to study the relation between the expression of Bcl-2 and the androgen receptor, as well as p21WAF1/CIP1 (p21), and cyclin D1 status, in a series of 89 prostate cancer samples taken before androgen withdrawal treatment.

Results—Androgen receptor negative tumours expressed significantly higher amounts of Bcl-2 than those prostate carcinomas with low/medium androgen receptor values. However, in tumours expressing the highest amounts of androgen receptor, Bcl-2 expression was also high. A significant positive relation between Bcl-2 and p21 expression, as well as an inverse relation between Bcl-2 and cyclin D1 expression, was noted. Androgen receptor positive samples also expressed significantly higher amounts of cyclin D1.

Conclusions—These results suggest that p21 and cyclin D1 expression in prostatic cancer might be modulated by Bcl-2 and by androgens and in turn this could be relevant to the progression of prostatic cancer.

Key Words: prostatic cancer • hormone independency • Bcl-2 • androgen receptor • p21WAF1/CIP1 • cyclin D1

This article has been cited by other articles:

				K. Fizazi, L. A. Martinez, C. R. Sikes, D. A. Johnston, L. C. Stephens, T. J. McDonnell, C. J. Logothetis, J. Trapman, L. L. Pisters, N. G. Ordonez, et al. The Association of p21(WAF-1/CIP1) with Progression to Androgen-independent Prostate Cancer Clin. Cancer Res., March 1, 2002; 8(3): 775 - 781. [Abstract] [Full Text] [PDF]

				K. A. Moffatt, W. U. Johannes, T. E. Hedlund, and G. J. Miller Growth Inhibitory Effects of 1{alpha}, 25-Dihydroxyvitamin D3 Are Mediated by Increased Levels of p21 in the Prostatic Carcinoma Cell Line ALVA-31 Cancer Res., October 1, 2001; 61(19): 7122 - 7129. [Abstract] [Full Text] [PDF]

				M. E. Taplin and S.-M. Ho The Endocrinology of Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477. [Full Text] [PDF]